The Aryl Hydrocarbon Receptor in Asthma: Friend or Foe?

被引:25
|
作者
Poulain-Godefroy, Odile [1 ]
Boute, Melodie [1 ]
Carrard, Julie [1 ]
Alvarez-Simon, Daniel [1 ]
Tsicopoulos, Anne [1 ]
de Nadai, Patricia [1 ]
机构
[1] Univ Lille, CHU Lille, CIIL Ctr Infect & Immunite Lille, Inst Pasteur Lille,INSERM,CNRS,U1019,UMR9017, F-59000 Lille, France
关键词
asthma; aryl hydrocarbon receptor; immunity; INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; ALLERGIC AIRWAY INFLAMMATION; DENDRITIC CELLS; CHILDHOOD ASTHMA; INTERLEUKIN; 22; AH RECEPTOR; MOUSE MODEL; ACTIVATION; DIFFERENTIATION;
D O I
10.3390/ijms21228797
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has emerged as an important player in asthma control. AhR is responsive to environmental molecules and endogenous or dietary metabolites and regulates innate and adaptive immune responses. Binding of this receptor by different ligands has led to seemingly opposite responses in different asthma models. In this review, we present two sides of the same coin, with the beneficial and deleterious roles of AhR evaluated using known endogenous or exogenous ligands, deficient mice or antagonists. On one hand, AhR has an anti-inflammatory role since its activation in dendritic cells blocks the generation of pro-inflammatory T cells or shifts macrophages toward an anti-inflammatory M2 phenotype. On the other hand, AhR activation by particle-associated polycyclic aromatic hydrocarbons from the environment is pro-inflammatory, inducing mucus hypersecretion, airway remodelling, dysregulation of antigen presenting cells and exacerbates asthma features. Data concerning the role of AhR in cells from asthmatic patients are also reviewed, since AhR could represent a potential target for therapeutic immunomodulation.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 50 条
  • [1] Aryl hydrocarbon receptor ligands in cancer: friend and foe
    Murray, Iain A.
    Patterson, Andrew D.
    Perdew, Gary H.
    NATURE REVIEWS CANCER, 2014, 14 (12) : 801 - 814
  • [2] Aryl hydrocarbon receptor ligands in cancer: friend and foe
    Iain A. Murray
    Andrew D. Patterson
    Gary H. Perdew
    Nature Reviews Cancer, 2014, 14 : 801 - 814
  • [3] The aryl hydrocarbon receptor in anticancer drug discovery: Friend or foe?
    Bradshaw, TD
    Trapani, V
    Vasselin, DA
    Westwell, AD
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (27) : 2475 - 2490
  • [4] The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?
    Mo, Yenan
    Lu, Zhaoyu
    Wang, Lixin
    Ji, Chunlan
    Zou, Chuan
    Liu, Xusheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [5] The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both
    Julliard, Walker
    Fechner, John H.
    Mezrich, Joshua D.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [6] MHEALTH IN ASTHMA - FRIEND OR FOE?
    Fowler, Stephen J.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (04) : A30 - A30
  • [7] Immunoglobulin A in asthma: friend or foe?
    Hiemstra, PS
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (03) : 517 - 518
  • [8] Autophagy: A Friend or Foe in Allergic Asthma?
    Theofani, Efthymia
    Xanthou, Georgina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [9] Infection: friend or foe to the development of asthma?
    Carlsen, KH
    Sterk, PJ
    EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (05) : 744 - 747
  • [10] Asthma disease management: Friend or foe?
    Kennerly, D
    ALLERGY AND ASTHMA PROCEEDINGS, 1999, 20 (05) : 293 - 298